After 12 years, millions of dollars, and a major reversal of fortune, Amicus Therapeutics won Food and Drug Administration approval on Friday for its first therapy, a treatment for a rare and sometimes deadly disease.

The drug, called Galafold, targets Fabry disease, an inherited disorder in which the lack of a key enzyme leads to buildups up fats that can cause fatal organ damage. As it stands, Fabry patients rely on costly, bimonthly injections of synthetic enzymes to keep symptoms at bay. Amicus’s drug is an every-other-day pill that works not by replacing the missing enzyme but by boosting the effects of what patients already produce.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • This article fails to point out that the US phase 3 trial failed to hit statistical significance and the EU phase 3 trial had a serious patient imbalance where the Galafold arm had a bunch of patients with a less sick genotype.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy